Phase
Condition
Stress
Circulation Disorders
Vascular Diseases
Treatment
N/AClinical Study ID
Ages 18-89 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Written informed consent to participate in the study obtained from the subject orlegal representative a) prior to initiation of any study mandated procedure
- Japanese subjects who have been diagnosed as having CTEPH:
- Subjects who have not undergone balloon pulmonary angioplasty (BPA) and for whomthe investigator determines not to implement pulmonary endarterectomy (PEA) atthe time of the acquisition of informed consent due to the organized thrombosislocalized in the peripheral regions, high risk (complications, old age, etc.) orfor any other reasons.
- Subjects who have postoperative persistent or recurrent pulmonary hypertension (PH) after undergoing pulmonary endarterectomy (PEA) and/or BPA.
- PH subjects whose WHO FC is I to IV
- 6MWD measured during the screening period ranges from 150 m to 450 m
- Subjects who meet the following conditions according to the right heartcatheterization (RHC) performed during the screening period or within 8 weeks beforethe acquisition of the informed consent:
- Resting mean pulmonary arterial pressure (mPAP) ≥ 25 mmHg
- Pulmonary artery wedge pressure (PAWP) ≤ 15 mmHg (if PAWP cannot be measured orthe value of PAWP is not reliable, left ventricular end-diastolic pressure ≤ 13mmHg)
- Resting PVR ≥ 400 dyn*sec/cm5
- Subjects treated with anti-coagulation agents, unfractionated heparin or low molecularweight heparin at least 90 days prior to RHC at baseline
- Women with childbearing potential with negative serum pregnancy test results and ableto follow the appropriate contraceptive methods from the date of starting the studydrug administration up to 30 days after the discontinuation or completion of the studydrug administration. Fertile male subjects able to use condom during the same period.
Exclusion
Exclusion Criteria:
- BPA within 90 days prior to undergoing baseline RHC
- PEA within 180 days prior to undergoing baseline RHC
- Subjects with unstable pulmonary hemodynamics who have postoperative persistent orrecurrent PH after undergoing PEA and/or BPA
- Recurrent thromboembolism undergoing treatment with oral anti-coagulation agents
- Symptomatic acute pulmonary embolism within 180 days prior to the start of study drugadministration
- Known moderate-to-severe restrictive lung disease or obstructive lung disease or knownsignificant chronic lung disease diagnosed by chest imaging (e.g., interstitial lungdisease, emphysema)
- Acute myocardial infarction during Screening period
- Severe liver impairment.
- Systolic blood pressure (SBP) < 90 mmHg at screening.
- Any known factor or disease that may interfere with treatment compliance or fullparticipation in the study
Study Design
Connect with a study center
Fukuoka University Nishijin Hospital
Fukuoka, 814-8522
JapanSite Not Available
Fukushima Medical University Hospital
Fukushima, 960-1247
JapanSite Not Available
Kagoshima University Hospital
Kagoshima, 890-8520
JapanSite Not Available
Nara Medical University Hospital
Kashihara, 634-8522
JapanSite Not Available
Kokura Kinen Hospital
Kitakyushu, 802-8555
JapanSite Not Available
Kokura Kinen Hospital
Kitakyusyu, 802-8555
JapanSite Not Available
Kobe University Hospital
Kobe, 650-0017
JapanSite Not Available
Saitama Cardiovascular and Respiratory Center
Kumagaya, 360-0197
JapanSite Not Available
Kure Kyosai Hospital
Kure, 737-8505
JapanSite Not Available
Kurume University Hospital
Kurume, 830-0011
JapanSite Not Available
Toho University Ohashi Medical Center
Meguro-ku, 153-8515
JapanSite Not Available
IIUHW Mita Hospital
Minato-ku, 108-8329
JapanSite Not Available
Kyorin University Hospital
Mitaka, 181-8611
JapanSite Not Available
Nagasaki University Hospital
Nagasaki, 852-8501
JapanSite Not Available
National Hospital Organization Okayama Medical Center
Okayama, 701-1192
JapanSite Not Available
Hokkaido University Hospital
Sapporo, 060-8648
JapanSite Not Available
Sapporo Medical University Hospital
Sapporo, 060-8543
JapanSite Not Available
Sasebo City General Hospital
Sasebo, 857-8511
JapanSite Not Available
Keio University Hospital
Shinjuku-ku, 160-0016
JapanSite Not Available
National Cerebral and Cardiovascular Center Hospital
Suita, 565-8565
JapanSite Not Available
Mie University Hospital
Tsu, 514-8507
JapanSite Not Available
University of Tsukuba Hospital
Tsukuba, 305-8576
JapanSite Not Available
Yamagata University Hospital
Yamagata, 990-0828
JapanSite Not Available
Yokohama City University Hospital
Yokohama, 236-0004
JapanSite Not Available
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.